Continue to Site

The most innovative pharmaceutical agents of 2020

By Danielle Kirsh | August 3, 2020

Vyndaqel/Vyndamax

Pfizer

Vyndaqel and Vyndamax are designed for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults.

The pharmaceutical agents reduce cardiovascular mortality and cardiovascular-related hospitalizations. They are transthyretin stabilizer tafamidis.

Most common side effects include urinary tract infection, vaginal infection, upper abdominal pain and diarrhea.

Next >>

Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs
Tagged With: AbbVie, Adlon Therapeutics, Advanced Accelerator Applications, Astellas Pharma, Bayer, Eli Lilly & Co., Galien Foundation, Genentech, Greenwich Biosciences, GW Pharmaceuticals, Janssen Biotech, Johnson & Johnson, Karyopharm Therapeutics, Medicines Development for Global Health, Merck, Novartis, Pfizer, Population Council, Purdue Pharma, Roche Group, Servier Pharmaceuticals, SIGA Technologies, Sobi, TB Alliance, Theravance Biopharma

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

About The Author

Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Market Summary > Current Price

The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Search Drug Discovery & Development